Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts

Tasquinimod is a novel inhibitor of tumor angiogenesis which enhances therapeutic efficacy when combined with androgen ablation and/or taxane‐based chemotherapies in pre‐clinical prostate cancer models. It has entered registration Phase III evaluation for the treatment of castration resistant prostate cancer. Since tasquinimod suppresses the angiogenic switch induced by tumor hypoxia as prostate cancers outgrow their blood supply, this raises the issue of whether tasquinimod also suppresses the angiogenic rebound induced by fractionated radiation thereby enhancing therapeutic response to fractionated radiation.

[1]  J. Isaacs.  The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer , 2010, Expert opinion on investigational drugs.

[2]  A. Armstrong,et al.  A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer (CRPC). , 2010 .

[3]  R. Weichselbaum,et al.  Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. , 2010, Cancer research.

[4]  J. Damber,et al.  Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer , 2009, British Journal of Cancer.

[5]  D. Gladstone,et al.  Repeated tumor pO(2) measurements by multi-site EPR oximetry as a prognostic marker for enhanced therapeutic efficacy of fractionated radiotherapy. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  Michael F. Milosevic,et al.  Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: A pilot study in men with prostate cancer , 2009, International journal of radiation biology.

[7]  D. Grignon,et al.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F. Tas,et al.  Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer , 2008, Cancer Chemotherapy and Pharmacology.

[9]  David J Collins,et al.  Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. , 2007, International journal of radiation oncology, biology, physics.

[10]  C. Ménard,et al.  Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. , 2007, Cancer research.

[11]  J. Isaacs,et al.  The quinoline‐3‐carboxamide anti‐angiogenic agent, tasquinimod, enhances the anti‐prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts , 2007, The Prostate.

[12]  D. Qian,et al.  Identification of ABR‐215050 as lead second generation quinoline‐3‐carboxamide anti‐angiogenic agent for the treatment of prostate cancer , 2006, The Prostate.

[13]  C. Ling,et al.  Measurements of Partial Oxygen Pressure (pO2) using the OxyLite System in R3327-AT Tumors under Isoflurane Anesthesia , 2006, Radiation research.

[14]  V. Grégoire,et al.  Early reoxygenation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions. , 2005, International journal of radiation oncology, biology, physics.

[15]  J. Isaacs,et al.  Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of Malignant versus Normal Prostate Epithelial Cells , 2004, Cancer Research.

[16]  M. Dewhirst,et al.  Raising the Bar: How HIF-1 Helps Determine Tumor Radiosensitivity , 2004, Cell cycle.

[17]  L. Beckett,et al.  Survival and cell cycle kinetics of human prostate cancer cell lines after single- and multifraction exposures to ionizing radiation. , 2004, International journal of radiation oncology, biology, physics.

[18]  Pamela Catton,et al.  Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[19]  Zvi Fuks,et al.  Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis , 2003, Science.

[20]  U. Dirnagl,et al.  Isoflurane induced prolonged protection against cerebral ischemia in mice: a redox sensitive mechanism? , 2002, Neuroreport.

[21]  A. Hanlon,et al.  Hypoxia in Human Prostate Carcinoma: An Eppendorf Po2 Study , 2001, American journal of clinical oncology.

[22]  M. Adam,et al.  Oxygen tension measurements of tumors growing in mice. , 1999, International journal of radiation oncology, biology, physics.

[23]  Bert Vogelstein,et al.  Cell-cycle arrest versus cell death in cancer therapy , 1997, Nature Medicine.

[24]  J. Isaacs,et al.  Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. , 1997, Cancer research.

[25]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[26]  E. Hall,et al.  Radiobiology for the Radiologist, 6th Edition , 2006 .

[27]  R. Bouvier,et al.  Prostate Inhibitor Thrombospondin-1 in Normal and Neoplastic Androgens Repress the Expression of the Angiogenesis , 2004 .

[28]  H. Sack,et al.  Tumour oxygenation during fractionated radiotherapy--comparison with size-matched controls. , 1999, Acta oncologica.